Effect of antiepileptic drugs on somatostatin release in vitro

Somatostatin release in rat neocortex during gamma-hydroxybutyrate-provoked seizures: Microdialysis combined with EEG recording

Gamma-hydroxybutyrate (GHB) was intracortically applied in two doses (first 10 and then 20 mg/ml) to awake Wistar rats using microdialysis. Simultaneously, EEG and the release of somatostatin-like immunoreactivity (SLI) were measured from the frontal cortex. Intracerebrally administered GHB induced cortical epileptogenic spikes, but not high voltage spindles (HVS) as reported after systemic administration, and seizures with myoclonic jerks and contraversive head movements. Compared to the basal level, GHB (10 mg/ml) initially increased the release of SLI (p < 0.05). However, when the frequency of spikes and seizures rose rapidly (p < 0.001), SLI release decreased significantly (p < 0.001). Minimum release of SLI occurred when seizures were most frequent (during perfusion with 20 mg/ml GHB), while after removal of the drug it rose above the basal level (p < 0.05). According to these results, intracortically applied GHB increases the release of SLI in the surrounding tissue. However, further exposure of GHB leads to a manifestation of epileptic spikes and seizures, during which the release of SLI is significantly attenuated. This suggests that release of somatostatin is affected during epileptic phenomena induced also by intracortical GHB application.

Anticonvulsants inhibit rat neuronal somatostatin release

Somatostatin (SRIF), a peptide widely distributed in the central nervous system, has been implicated in the genesis of seizure activity in a number of animal models of epilepsy. We examined the effects of the anticonvulsants, phenytoin, carbamazepine and diazepam, on the release of SRIF from dispersed adult rat neuronal cells in short-term culture. Each of these agents caused dose-dependent inhibition of ouabain-stimulated SRIF release in a well-characterized hypothalamic dispersed cell system. We also examined the effects of phenytoin on SRIF release from dispersed rat cortical cells and inhibition of stimulated SRIF secretion was again observed. These findings support the hypothesis that the inhibition of neuronal SRIF release may represent a pharmacological mechanism of action of anticonvulsants.

Vigabatrin pre-treatment prevents hilar somatostatin cell loss and the development of interictal spiking activity following sustained simulation of the perforant path

Somatostatin-containing neurons in the hilus of the dentate gyrus are known to be exceptionally vulnerable in experimental models of epilepsy, as well as in human temporal lobe epilepsy. The position of these cells in the circuitry of the dentate gyrus is ideal for gating the activation evoked by afferents from the entorhinal cortex. In the present study we have shown that the loss of hilar somatostatin-containing neurons, and the development of interictal spiking activity induced by sustained perforant pathway stimulation can be prevented by high doses (500 mg/kg), but not by low doses (100 mg/kg) of vigabatrin, an irreversible inhibitor of GABA-transaminase.